788 related articles for article (PubMed ID: 28480903)
1. Metabolic reprogramming in clear cell renal cell carcinoma.
Wettersten HI; Aboud OA; Lara PN; Weiss RH
Nat Rev Nephrol; 2017 Jul; 13(7):410-419. PubMed ID: 28480903
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
Weiss RH
Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
[TBL] [Abstract][Full Text] [Related]
3. Metabolic reprogramming in renal cancer: Events of a metabolic disease.
Chakraborty S; Balan M; Sabarwal A; Choueiri TK; Pal S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188559. PubMed ID: 33965513
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
[TBL] [Abstract][Full Text] [Related]
5. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.
Wang J; Zhang P; Zhong J; Tan M; Ge J; Tao L; Li Y; Zhu Y; Wu L; Qiu J; Tong X
Oncotarget; 2016 May; 7(19):27142-57. PubMed ID: 27049827
[TBL] [Abstract][Full Text] [Related]
6. Tobacco smoking induces metabolic reprogramming of renal cell carcinoma.
Reigle J; Secic D; Biesiada J; Wetzel C; Shamsaei B; Chu J; Zang Y; Zhang X; Talbot NJ; Bischoff ME; Zhang Y; Thakar CV; Gaitonde K; Sidana A; Bui H; Cunningham JT; Zhang Q; Schmidt LS; Linehan WM; Medvedovic M; Plas DR; Figueroa JAL; Meller J; Czyzyk-Krzeska MF
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32970633
[TBL] [Abstract][Full Text] [Related]
7. SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-κB signaling.
Yang H; Zhang X; Liu F; Fan J; Wang B; Dong C
Biochem Biophys Res Commun; 2018 Jan; 495(1):1383-1388. PubMed ID: 29183723
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming of clear cell renal cell carcinoma.
Zhu H; Wang X; Lu S; Ou K
Front Endocrinol (Lausanne); 2023; 14():1195500. PubMed ID: 37347113
[TBL] [Abstract][Full Text] [Related]
9. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis.
Ma Y; Qi Y; Wang L; Zheng Z; Zhang Y; Zheng J
Free Radic Biol Med; 2019 Apr; 134():458-467. PubMed ID: 30703481
[TBL] [Abstract][Full Text] [Related]
10. c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma.
Huang J; Kong W; Zhang J; Chen Y; Xue W; Liu D; Huang Y
Int J Oncol; 2016 Oct; 49(4):1569-75. PubMed ID: 27431728
[TBL] [Abstract][Full Text] [Related]
11. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.
Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH
Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651
[TBL] [Abstract][Full Text] [Related]
12. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
[TBL] [Abstract][Full Text] [Related]
13. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming of Metabolism in Kidney Cancer.
Wettersten HI
Semin Nephrol; 2020 Jan; 40(1):2-13. PubMed ID: 32130963
[TBL] [Abstract][Full Text] [Related]
15. Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.
Courtney KD; Bezwada D; Mashimo T; Pichumani K; Vemireddy V; Funk AM; Wimberly J; McNeil SS; Kapur P; Lotan Y; Margulis V; Cadeddu JA; Pedrosa I; DeBerardinis RJ; Malloy CR; Bachoo RM; Maher EA
Cell Metab; 2018 Nov; 28(5):793-800.e2. PubMed ID: 30146487
[TBL] [Abstract][Full Text] [Related]
16. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
[TBL] [Abstract][Full Text] [Related]
17. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
18. A river model to map convergent cancer evolution and guide therapy in RCC.
Wei EY; Hsieh JJ
Nat Rev Urol; 2015 Dec; 12(12):706-12. PubMed ID: 26526752
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma and proteomics.
Sandim V; Pereira DA; Ornellas AA; Alves G
Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
